A physician-scientist at the University of Oklahoma is part of an international effort seeking new options for patients with head and neck cancer who cannot receive the standard chemotherapy drug cisplatin.
European court rules Teva, Cephalon must pay $60M fine for reverse payment scheme after failed appeal
Teva and its subsidiary Cephalon’s hopes that a European court would dismiss or reduce more than $60 million in fines have been dashed after the
October 20, 2023